The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2015 | Emerging anti-CD20 monoclonal antibodies as first-line therapy in elderly CLL
At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the results of clinical trials of anti-CD20 monoclonal antibodies in combination with chloramubucil, obinutuzumab plus chloramubucil and ofatumumab plus chlorambucil, for first-line therapy in older patients with chronic lymphocytic leukemia (CLL).
